Exosomes; multifaceted nanoplatform for targeting brain cancers
At the moment, anaplastic changes within the brain are challenging due to the complexity of neural tissue, leading to the inefficiency of therapeutic protocols. The existence of a cellular interface, namely the blood-brain barrier (BBB), restricts the entry of several macromolecules and therapeutic...
Gespeichert in:
Veröffentlicht in: | Cancer letters 2023-03, Vol.557, p.216077-216077, Article 216077 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | At the moment, anaplastic changes within the brain are challenging due to the complexity of neural tissue, leading to the inefficiency of therapeutic protocols. The existence of a cellular interface, namely the blood-brain barrier (BBB), restricts the entry of several macromolecules and therapeutic agents into the brain. To date, several nano-based platforms have been used in laboratory settings and in vivo conditions to overcome the barrier properties of BBB. Exosomes (Exos) are one-of-a-kind of extracellular vesicles with specific cargo to modulate cell bioactivities in a paracrine manner. Regarding unique physicochemical properties and easy access to various biofluids, Exos provide a favorable platform for drug delivery and therapeutic purposes. Emerging data have indicated that Exos enable brain penetration of selective cargos such as bioactive factors and chemotherapeutic compounds. Along with these statements, the application of smart delivery approaches can increase delivery efficiency and thus therapeutic outcomes. Here, we highlighted the recent advances in the application of Exos in the context of brain tumors.
•Therapeutics entry into brain is challenging because of BBB barrier properties.•Exosomes, nanometer vesicles, provide reliable platform for delivery purposes.•Exosomes cross BBB due to physiochemical properties using certain mechanisms.•Therapeutics are loaded into exosome lumen/surface using different techniques.•Surface modification and BBB receptor targeting enhance exosome crossing. |
---|---|
ISSN: | 0304-3835 1872-7980 |
DOI: | 10.1016/j.canlet.2023.216077 |